metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	avelumab alone vs. paclitaxel	1	1.10 [0.88; 1.37], 1 RCT, I2=0% inconclusive result	1.73 [1.38; 2.17], 1 RCT, I2=0% statistically significant harm	-
	pembrolizumab alone vs. paclitaxel	1	0.94 [0.79; 1.12], 1 RCT, I2=0% inconclusive result	1.49 [1.25; 1.77], 1 RCT, I2=0% statistically significant harm	-
versus placebo
	nivolumab alone vs. placebo	1	0.63 [0.51; 0.78], 1 RCT, I2=0% unassessable degree of certainty	0.60 [0.48; 0.74], 1 RCT, I2=0% unassessable degree of certainty	-
versus Standard of Care (SoC)
	Ipilimumab (10 mg/kg) vs. Standard of Care (SoC)	1	1.54 [0.73; 3.26], 1 RCT, I2=0% inconclusive result	1.59 [1.20; 2.10], 1 RCT, I2=0% statistically significant harm	-
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone vs. paclitaxel	1	0.82 [0.66; 1.02], 1 RCT, I2=0% inconclusive result	1.27 [1.03; 1.57], 1 RCT, I2=0% statistically significant harm	-